---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-26-000097"
form_type: "8-K"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:43:17.076791+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pelthos secures up to $50M senior secured term loan from Horizon; $30M drawn at close

## Summary
- Up to $50M senior secured term loan facility from Horizon Technology Finance; $30M funded at closing on Jan 12, 2026.
- Remaining $20M available upon achieving milestones; interest rate prime +3.75% (currently 10.50%) with 6.75% floor.
- Proceeds to commercialize ZELSUVMI, launch Xepi and Xeglyze, and for working capital.
- Issued warrants for 65,488 shares at $27.49 per share to Horizon; loan matures Jan 31, 2031.
- As of Sept 30, 2025, cash and investments $14.2M; augmented by $18M convertible notes in Nov 2025.

## SEC filing metadata
- accession: 0001753926-26-000097
- form_type: 8-K
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000175392626000097/0001753926-26-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000175392626000097/g085079_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-26-000097
- JSON: https://secwatch.observer/filing/0001753926-26-000097.json
- Plain text: https://secwatch.observer/filing/0001753926-26-000097.txt

## Source-grounded claims
- claim_id: 09102d8c28c8c6d9bdfc958467bd1a6ba0eba1f0
  claim: Pelthos Therapeutics Inc. entered into Venture Loan and Security Agreement with Horizon Technology Finance Corporation valued at aggregate principal amount of up to $50.0 million (effective 2026-01-12).
  evidence_excerpt: On January 12, 2026 (the “ Closing Date ”), Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), LNHC, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ LNHC ”) and Channel Pharmaceutical Corporation, a Nevada corporation and a wholly subsidiary of the Company (“ Channel ”), as co-borrowers (together with the Company, the “ Borrowers ”), entered into a Venture Loan and Security Agreement (the “ Loan Agreement ”) by and among the Borrowers and Horizon Technology Finance Corporation, a Delaware corporation, as lender and collateral agent (the “ Lender ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1919246/000175392626000097/0001753926-26-000097-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.